Search Bar & Filters
Found 171 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are developing and conducting early validation of a wearable sensor designed to detect and assist with swallowing difficulties dysphagia in patients with Parkinsons Disease PD. The study aims to improve the sensors battery life and size, evaluate user experience with Parkinsons patients, and test the sensors ability to monitor swallowing and provide vibratory cues to increase swallow frequency. This project addresses important challenges in managing swallowing and drooling problems associated with PD. The intervention involves the Aria sensor, a wearable patch that continuously monitors physiological signals and delivers vibratory haptic cues to encourage swallowing. Participants will use the sensor over a 3-week period, with active vibratory cueing occurring only during the second week. The study includes phases focused on engineering improvements, patient feedback through focus groups, and feasibility testing of the sensors functionality. Participants will wear the sensor and undergo assessments to measure swallowing frequency and symptom changes. Evaluations include comparison with a gold standard over one year and monitoring changes in clinical scales related to drooling and swallowing from baseline to week 3. Researchers will also assess adherence to the haptic cueing during the intervention. The study tracks multiple outcomes to understand the sensors usability, effectiveness in detecting swallowing, and impact on symptoms in PD patients.
Actively Recruiting
This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.
Actively Recruiting
Researchers are evaluating ASP5541, a new form of abiraterone acetate given by muscle injection, in men with advanced prostate cancer. The study compares ASP5541, with or without prednisoneprednisolone, to standard abiraterone acetate tablets plus prednisoneprednisolone. It aims to assess the safety and effectiveness of ASP5541 in men with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer who have not previously received androgen receptor pathway inhibitors. Participants are assigned to one of three groups men with metastatic castration-resistant prostate cancer receive either ASP5541 plus prednisoneprednisolone or abiraterone acetate plus prednisoneprednisolone men with metastatic hormone-sensitive prostate cancer receive either ASP5541 alone or abiraterone acetate with prednisoneprednisolone and Japanese men with either cancer type receive ASP5541 with prednisoneprednisolone. ASP5541 is administered by injection every 12 weeks, prednisoneprednisolone is taken orally once or twice daily depending on cancer type, and abiraterone acetate is taken daily as tablets. All participants continue standard androgen deprivation therapy. During the study, participants will have regular clinic visits for health monitoring and safety checks, with some checking blood pressure weekly at home. Imaging scans and laboratory tests will assess cancer progression and treatment effects. Researchers will measure outcomes such as prostate-specific antigen levels, safety events, testosterone suppression, and cancer progression. The study includes long-term follow-up for up to 84 months and aims to provide detailed information on the safety and efficacy of ASP5541 compared to existing treatments.
Actively Recruiting
Researchers are studying VLS-1488, an oral drug, in a first-in-human phase III trial involving adults with advanced cancers. The study aims to evaluate the safety, tolerability, and early effectiveness of VLS-1488 in different solid tumor types, including ovarian, lung, breast, and endometrial cancers. This includes understanding the drugs effects on tumors with chromosomal instability and exploring its potential in various cancer subtypes. The study has two main parts Dose Escalation and Dose Expansion. During Dose Escalation, participants receive different doses of VLS-1488 to identify the maximum tolerated dose and appropriate dose levels for further testing. Dose Expansion involves treating participants with selected doses to assess safety, drug interactions, food effects, and preliminary efficacy. VLS-1488 is given orally in 28-day cycles and continued until disease progression or unacceptable side effects occur. Participants will undergo regular evaluations including CT or MRI scans to measure tumor response, safety monitoring for side effects, and assessments of drug levels in the body. Researchers will track dose-limiting toxicities, serious adverse events, and treatment-related side effects up to 18 months, with some measures followed for up to 32 months. Results will help determine how well participants tolerate VLS-1488 and its impact on tumor control over time.
Actively Recruiting
Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate how an online mindfulness program affects mood and anxiety symptoms in adolescents aged 12 to 17 who are at high risk due to elevated trait negative affect. The study compares this mindfulness program to a supportive active comparison and a no-intervention control group. Researchers seek to understand if mindfulness reduces momentary negative feelings and prevents worsening internalizing symptoms such as anxiety and depression in youth. Participants are randomly assigned to one of three groups the Mindfulness Program involves nine weekly 30-minute online coached sessions teaching mindfulness skills the Supportive Active condition involves nine weekly 30-minute remote sessions with a coach focusing on discussing feelings and thoughts and the Control group completes assessments only. All groups are evaluated before the intervention, after about 10 weeks, and again at a six-month follow-up. Youth involvement includes completing ecological momentary assessments measuring negative affect and internalizing symptoms at baseline, post-intervention, and six months later. Researchers monitor changes in momentary negative affect as a key outcome, along with anxiety and depression symptoms. The study uses online sessions and remote coaching, aiming for broad accessibility and prevention of internalizing problems over approximately seven months of participation.
Actively Recruiting
Researchers are observing adults with lung cancer, specifically those planned for pulmonary segmentectomy, to understand outcomes after surgery. The study focuses on patients with clinical Stage I suspected non-small cell lung cancer NSCLC and aims to track disease-free survival over 3 and 5 years following surgery. This international registry collects real-world data to provide insights on this surgical approach. Participants undergo planned pulmonary segmentectomy for primary lung cancer. Patient-reported outcomes will be gathered using the Patient-Reported Outcomes Measurement Information System PROMIS, which evaluates physical function, pain interference, and dyspnea severity through web-based surveys. These assessments occur before surgery, between 2 to 4 weeks after surgery, and again 6 months post-surgery. Throughout the study, participants complete questionnaires at specified intervals to report on their health status. The research team will measure 3-year and 5-year disease-free survival rates following segmentectomy. The study spans several years, with the primary completion date in 2029, allowing long-term monitoring of participant outcomes and health progression.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.
1-10 of 171
1